GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Interest Expense

IRLAB Therapeutics AB (OSTO:IRLAB A) Interest Expense : kr-4.68 Mil (TTM As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. IRLAB Therapeutics AB's interest expense for the three months ended in Jun. 2024 was kr -2.48 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2024 was kr-4.68 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. IRLAB Therapeutics AB's Operating Income for the three months ended in Jun. 2024 was kr -5.10 Mil. IRLAB Therapeutics AB's Interest Expense for the three months ended in Jun. 2024 was kr -2.48 Mil. IRLAB Therapeutics AB did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

IRLAB Therapeutics AB Interest Expense Historical Data

The historical data trend for IRLAB Therapeutics AB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRLAB Therapeutics AB Interest Expense Chart

IRLAB Therapeutics AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.27 -0.20 -0.37 -0.30 -0.20

IRLAB Therapeutics AB Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.03 -0.08 -2.10 -2.48

IRLAB Therapeutics AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-4.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IRLAB Therapeutics AB  (OSTO:IRLAB A) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

IRLAB Therapeutics AB's Interest Expense for the three months ended in Jun. 2024 was kr-2.48 Mil. Its Operating Income for the three months ended in Jun. 2024 was kr-5.10 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2024 was kr2.60 Mil.

IRLAB Therapeutics AB's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as

IRLAB Therapeutics AB did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

IRLAB Therapeutics AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Interest Expense
Comparable Companies
OSTO:IMMU OSTO:NICA OSTO:SANION OSTO:GUARD OSTO:MVIR OSTO:KDEV OSTO:KAN OSTO:INDEX OSTO:IVACC OSTO:CLBIO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
6IRA:Germany
Address
Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
Website
https://www.irlab.se
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB Headlines

No Headlines